Abstract
We evaluated the feasibility of an automated tablet computer application providing a family and personal history based cancer risk assessment for hereditary breast, ovarian, endometrial and colorectal cancers. 1,002 women presenting for screening mammography and 1,000 presenting for ultrasound were offered screening. The application calculated the risk of BRCA mutations using BRCAPRO, Myriad and Tyrer–Cuzick risk assessment models. Lifetime risk of breast and ovarian cancer was assessed with the BRCAPRO, Claus and Tyrer–Cuzick models. Colorectal and endometrial cancer risk was calculated via the MMRpro model. Patients were identified as high-risk based on thresholds 10 % or greater risk for carrying genetic mutations or 20 % or greater lifetime risk of breast or ovarian cancer. The percent of women found to be high-risk by a single risk assessment tool ranged from 0.5 to 5.3 %. Combining assessment tools found 9.3 % of women to be high-risk. The risk assessments performed similarly for the mammography and ultrasound cohorts with yields (combining assessment tools) of 9.2 and 9.4 % respectively. The average ages of all the high-risk women were 45.8 and 39.6 years for the mammography and ultrasound cohorts respectively. Difficulties encountered included a need for software upgrade, wireless network unreliability and hardware theft. Automated family history screening can identify women probably at high-risk for hereditary cancers efficiently. The number of women identified is increased by employing multiple risk assessment models simultaneously. Surveying women in conjunction with ultrasound identified women at increased risk as effectively and at a younger age than with screening mammography.
Similar content being viewed by others
References
Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689
Struewing JP et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408
Easton DF et al (1995) Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56:265–271
Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA- mismatch-repair genes. Int J Cancer 81:214–218
Vasen F, Juul T et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027
Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325
Warner E, Plewes DB, Shumak RS et al (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19:3524–3531
Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23(33):8469–8476
Stirling D, Evans DG, Pichert G et al (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gyne- cology and Obstetrics System. J Clin Oncol 23:5588–5596
Jacobs IJ, Mackay J, Menon U et al. (2006) Familial ovarian screening—effective or ineffective? Br J Cancer 95:1124; author reply 1126–7
Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121:225–231
Calderon-Margalit R, Paltiel O (2004) Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 112:357–364
King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256
Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261–269
Smith KL, Robson ME (2006) Update on hereditary breast cancer. Curr Oncol Rep 8(1):14–21
Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84(1):16–28
Broaddus RR, Lu KH (2006) Women with HNPCC: a target population for the chemoprevention of gynecologic cancers. Front Biosci 11:2077–2080
Lu HK, Broaddus RR (2005) Gynecologic cancers in lynch syndrome/HNPCC. Fam Cancer 4(3):249–254
Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12):1507–1517
Ozanne EM, Loberg A, Hughes S et al (2009) Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast J 15(2):155–162
Brian Drohan MS, Ozanne EA, Hughes KS (2009) Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. Breast J 15(1):46–55
Jones JL, Hughes KS, Kopans DB et al (2005) Evaluation of hereditary risk in a mammography population. Clin Breast Cancer 6(1):38–44
Dominguez FJ, Jones JL, Zabicki K et al (2005) Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer 104(9):1849–1853
Hughes riskApps. Available www.hughesriskapps.com (first Accessed March 2007)
Saslow D et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89
Berry DA et al (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227–238
Claus E, Risch N, Thompson W (1994) Autosomal dominant inheritance of early- onset breast cancer. Implications for risk prediction. Cancer 73:643–651
Tyrer J, Duffy S, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111–1130
Myriad Genetic Laboratories, Inc. Available from URL: www.myriadpro.com (Accessed August 2006)
Chen S, Wang W, Lee S et al (2006) Colon cancer family registry. Prediction of germline mutations and cancer Rsk in the lynch syndrome. JAMA 296(12):1479–1487
NCCN GuidelinesTM, Version 1.2011, BSCR-A. Available www.nccn.org. Accessed April 2012
NCCN GuidelinesTM, Version 1.2011, HBOC-A1. Available www.nccn.org. Accessed April 2012
NCCN GuidelinesTM, Version 1.2012, LS-2. Available www.nccn.org. Accessed April 2012
Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for Breast-Cancer Prevention in Postmenopausal Women. N EnglJ Med 364:2381–2391
Domchek SM, Freibel TM, Singer CF et al (2010) Association of risk-reducing Surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967–975
Acknowledgments
This research was supported by a grant from Sutter Institute for Medical Research 2801 Capitol Avenue, Suite 400 Sacramento, CA 95816.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McDonnell, C.H., Seidenwurm, D.J., McDonnell, D.E. et al. Self administered screening for hereditary cancers in conjunction with mammography and ultrasound. Familial Cancer 12, 651–656 (2013). https://doi.org/10.1007/s10689-013-9641-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-013-9641-z